JP2007506765A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007506765A5 JP2007506765A5 JP2006528227A JP2006528227A JP2007506765A5 JP 2007506765 A5 JP2007506765 A5 JP 2007506765A5 JP 2006528227 A JP2006528227 A JP 2006528227A JP 2006528227 A JP2006528227 A JP 2006528227A JP 2007506765 A5 JP2007506765 A5 JP 2007506765A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- represented
- cholecalciferol
- acetyl
- dihydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 34
- 201000010099 disease Diseases 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000011647 vitamin D3 Substances 0.000 claims 22
- 229940021056 vitamin d3 Drugs 0.000 claims 22
- 230000002159 abnormal effect Effects 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 claims 8
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 230000033228 biological regulation Effects 0.000 claims 3
- 210000003890 endocrine cell Anatomy 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 210000002449 bone cell Anatomy 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 230000003831 deregulation Effects 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000006058 immune tolerance Effects 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 210000004927 skin cell Anatomy 0.000 claims 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010069632 Bladder dysfunction Diseases 0.000 claims 1
- 206010063408 Bladder hypertrophy Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000036495 Gastritis atrophic Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000001126 Keratosis Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010031240 Osteodystrophy Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 102000003982 Parathyroid hormone Human genes 0.000 claims 1
- 108090000445 Parathyroid hormone Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 102100028255 Renin Human genes 0.000 claims 1
- 108090000783 Renin Proteins 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 1
- 206010039984 Senile osteoporosis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000032594 Vascular Remodeling Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047124 Vasculitis necrotising Diseases 0.000 claims 1
- -1 Vitamin D 3 compound Chemical class 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000028996 habitual spontaneous abortion Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 239000000199 parathyroid hormone Substances 0.000 claims 1
- 229960001319 parathyroid hormone Drugs 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000007442 rickets Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000002229 urogenital system Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- HJVMSQILUSRILX-LUWJRPAHSA-N C[C@H](C/C=C/[C@](C)(C(F)(F)F)O)C([C@@]1(C)CCC2)=CCC1/C2=C/C=C(/C[C@H](C[C@@H]1OC(C)=O)OC(C)=O)\C1=C Chemical compound C[C@H](C/C=C/[C@](C)(C(F)(F)F)O)C([C@@]1(C)CCC2)=CCC1/C2=C/C=C(/C[C@H](C[C@@H]1OC(C)=O)OC(C)=O)\C1=C HJVMSQILUSRILX-LUWJRPAHSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50573503P | 2003-09-24 | 2003-09-24 | |
| GB0322395A GB0322395D0 (en) | 2003-09-24 | 2003-09-24 | Methods for treating bladder dysfunction and related compounds and compositions |
| GB0404567A GB0404567D0 (en) | 2004-03-01 | 2004-03-01 | Methods for treating bladder dysfunction and related compounds and compositions |
| PCT/US2004/031412 WO2005030222A1 (en) | 2003-09-24 | 2004-09-24 | 1,3-diaclyated,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007506765A JP2007506765A (ja) | 2007-03-22 |
| JP2007506765A5 true JP2007506765A5 (enExample) | 2007-11-15 |
Family
ID=39170491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006528227A Withdrawn JP2007506765A (ja) | 2003-09-24 | 2004-09-24 | １，３−ジアシル化２６，２７−アルキル／ハロアルキルビタミンｄ３化合物及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20080064668A1 (enExample) |
| EP (1) | EP1663249A4 (enExample) |
| JP (1) | JP2007506765A (enExample) |
| AU (1) | AU2004275815A1 (enExample) |
| CA (1) | CA2539708A1 (enExample) |
| WO (1) | WO2005030222A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006036813A2 (en) * | 2004-09-24 | 2006-04-06 | Bioxell S.P.A. | 20-cycloalkyl,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof |
| WO2006113990A2 (en) * | 2005-04-25 | 2006-11-02 | Cytochroma Inc. | LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1α ,25-DIHYDROXY VITAMIN D3 |
| EP1723965A1 (en) * | 2005-05-18 | 2006-11-22 | Stallergenes Sa | Compositions for antigen-specific induction of immuno-tolerance via oral immunization |
| WO2007039322A1 (en) * | 2005-09-19 | 2007-04-12 | Bioxell Spa | Use of vitamin d3 compounds for the treatment of uveitis |
| EP1968383B1 (en) | 2005-12-12 | 2011-05-11 | Women and Infants Hospital of Rhode Island | Derivatives of vitamin d and therapeutic use thereof |
| US9205080B2 (en) * | 2006-11-16 | 2015-12-08 | Transderm, Inc. | Methods of treating keratin hyperproliferation disorders using mTOR inhibitors |
| HUE073014T2 (hu) * | 2007-04-25 | 2025-12-28 | Opko Renal Llc | Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén |
| WO2009115398A1 (en) * | 2008-03-18 | 2009-09-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vitamin d compounds for the treatment of biliary diseases |
| AU2009251508A1 (en) * | 2008-04-18 | 2009-12-03 | The University Of Tennessee Research Foundation | Single nucleotide polymorphisms (SNP) and association with resistance to immune tolerance induction |
| CN103429234B (zh) | 2010-12-10 | 2016-10-05 | 布罗迪健康科学有限公司 | 茉莉酮酸酯治疗膀胱功能障碍的用途 |
| AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
| CN104758300A (zh) * | 2014-01-02 | 2015-07-08 | 上海泽生科技开发有限公司 | 维生素d及其组合物的抗菌用途 |
| WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| EP3565520B1 (en) | 2017-01-06 | 2026-02-25 | Palvella Therapeutics, Inc. | Anhydrous compositions of mtor inhibitors and methods of use |
| US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
| KR20250075704A (ko) | 2022-09-30 | 2025-05-28 | 익스텐드 바이오사이언시즈, 인크. | 장기-지속형 부갑상선 호르몬 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665387A (en) * | 1994-09-01 | 1997-09-09 | K.U. Leuven Research & Development | Methods and compositions for primary and secondary prevention of autoimmune diabetes |
| US5976784A (en) * | 1996-09-20 | 1999-11-02 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
| WO1999012894A1 (en) * | 1997-09-08 | 1999-03-18 | F. Hoffmann-La Roche Ag | 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analogs |
| WO2002094247A2 (en) * | 2001-05-22 | 2002-11-28 | Bioxell S.P.A. | Use of a vitamin d3 analogue for the treatment of autoimmune diabetes |
| WO2004098507A2 (en) * | 2003-04-30 | 2004-11-18 | Bioxell S.P.A. | 1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof |
-
2004
- 2004-09-24 JP JP2006528227A patent/JP2007506765A/ja not_active Withdrawn
- 2004-09-24 US US10/572,995 patent/US20080064668A1/en not_active Abandoned
- 2004-09-24 EP EP04789014A patent/EP1663249A4/en not_active Withdrawn
- 2004-09-24 WO PCT/US2004/031412 patent/WO2005030222A1/en not_active Ceased
- 2004-09-24 CA CA002539708A patent/CA2539708A1/en not_active Abandoned
- 2004-09-24 AU AU2004275815A patent/AU2004275815A1/en not_active Abandoned
-
2006
- 2006-03-21 US US11/386,494 patent/US20060258630A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007506765A5 (enExample) | ||
| EP4328230A2 (en) | Amino acid compounds and methods of use | |
| JP2009525981A5 (enExample) | ||
| UA129208C2 (uk) | Заміщені спіропохідні з прямим ланцюгом | |
| RU2013144579A (ru) | Ингибиторы киназы mst1 и способы их применения | |
| AU717429B2 (en) | Pyrrolo(3,4-(D)pyrimidinone derivatives and their use as medicaments | |
| UA120764C2 (uk) | Конденсовані пентациклічні похідні імідазолу | |
| WO2000071537A1 (en) | New pharmaceutically active compounds | |
| EP1045850A1 (en) | Purine compounds having pde iv inhibitory activity and methods of synthesis | |
| JP2006525367A5 (enExample) | ||
| JP2017508733A5 (enExample) | ||
| JP2007504128A5 (enExample) | ||
| CA2550660A1 (en) | Florfenicol prodrug having improved water solubility | |
| JP2008514621A5 (enExample) | ||
| IE891328L (en) | 4-quinoline carboxylic acid derivatives useful as¹immunosuppressive agents | |
| JP2007525494A5 (enExample) | ||
| JP2008538114A5 (enExample) | ||
| EP2297138A1 (en) | Processes for the preparation of crystalline forms of sunitinib malate | |
| HUP0300386A2 (hu) | Új (amino-propil)-metil-foszfinsavak | |
| TWI600644B (zh) | 二甲基吡啶胺衍生物及其醫藥用途 | |
| JP2014518870A5 (enExample) | ||
| EP2709998A1 (en) | Substituted indole derivatives for the treatment of immunological disorders | |
| AU2012257345A1 (en) | Substituted indole derivatives for the treatment of immunological disorders | |
| JP2013545729A5 (enExample) | ||
| WO2006129688A1 (ja) | ２－アミノブタノール化合物及びその医薬用途 |